Methods and compositions for treating endometriosis
Inventors
EQUELS, Thomas K. • Strayer, David R.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12102649-B2
Publication Date
2024-10-01
Expiration Date
Abstract
Disclosed is a method for treating endometriosis, preventing endometriosis, or ameliorating a symptom of endometriosis in a subject comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic dsRNA (tdsRNA).
Core Innovation
The invention relates to treating endometriosis or ameliorating a symptom of endometriosis in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic double stranded RNA (tdsRNA) as an active ingredient. The tdsRNA is selected from rI n·r(CxU)n and rugged dsRNA, with x selected from a defined group of values and n from 40-40,000.
The invention further defines forms and structural and size constraints for the tdsRNA used in the treatment. Dependent claim language specifies additional quantitative characteristics, including helical turns, molecular weight, and dsRNA size/basepair distribution constraints, and narrows selection to rugged dsRNA with defined strand composition and hybridization behavior. Other dependent language narrows administration routes and specifies optional combination administration with interferon.
In addition, the invention includes a composition for treating endometriosis or ameliorating a symptom using tdsRNA selected from rI n·r(CxU)n and rugged dsRNA, with the same defined x and n ranges. Another method variant defines a pharmaceutical composition that does not contain rugged dsRNA and further imposes quantitative dsRNA composition requirements based on the fraction of dsRNA larger than 40 basepairs and the fraction smaller than 10,000 basepairs.
Claims Coverage
The partial content provides three independent claims: clm-00001 (a method), clm-00016 (a composition), and clm-00019 (a method variant). Across these independent claims, the core inventive elements are the treatment of endometriosis via therapeutically effective administration of defined tdsRNA types and parameter constraints, with one claim variant additionally requiring absence of rugged dsRNA and imposing dsRNA size distribution thresholds; dependent coverage includes optional interferon combination and formulation constraints.
Therapeutically effective tdsRNA for treating endometriosis
Administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a therapeutic double stranded RNA (tdsRNA), wherein the tdsRNA is selected from the group consisting of rI n·r(CxU)n and rugged dsRNA, with x selected from the defined group and n from 40-40,000.
Endometriosis treatment composition with defined tdsRNA parameterization
A composition for treating endometriosis or ameliorating a symptom of endometriosis in a subject comprising tdsRNA selected from the group consisting of rI n·r(CxU)n and rugged dsRNA, wherein x is one or more selected from the defined group and wherein n is from 40-40,000.
Non-rugged tdsRNA method with dsRNA size distribution thresholds
A method for treating endometriosis or ameliorating a symptom of endometriosis in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic double stranded RNA (tdsRNA) that is rI n·r(CxU)n; wherein the pharmaceutical composition does not contain rugged dsRNA; wherein x is selected from the defined group; wherein n is from 40 to 40,000; wherein the tdsRNA contains a minimum of 90 wt % of dsRNA larger than 40 basepairs; and wherein the tdsRNA contains a minimum of 90 wt % of dsRNA smaller than 10,000 basepairs.
The independent claim set consistently centers on treating endometriosis by administering a therapeutically effective pharmaceutical composition whose active ingredient is parameter-defined therapeutic double stranded RNA (tdsRNA) of rI n·r(CxU)n and/or rugged dsRNA. One independent claim variant further specifies a non-rugged composition and imposes quantitative dsRNA size distribution requirements based on basepair thresholds.
Stated Advantages
Treating endometriosis or ameliorating a symptom of endometriosis.
Documented Applications
Use of the described methods and compositions for treating endometriosis or ameliorating an endometriosis symptom in a subject.
Interested in licensing this patent?